November 17, 2026

Actinium Pharmaceuticals Provides Third Quarter 2026 Corporate Update Highlighting ATNM-400 and Other Business Progress

- *Announced HER3 as the target of ATNM-400 and presented initial data from the first-in- human HERACT-PRO-1 Phase 1/2a study in metastatic castration-resistant prostate cancer (mCRPC) at EANM 2026*
- *Initiated RADIANZ pan-tumor imaging study to inform ATNM-400 development across multiple solid tumors beyond prostate cancer*
- *Formed Scientific Advisory Board and strengthened leadership team to support strategic execution, business development and continued pipeline advancement*
- *KOL webinar on ATNM-400 on December 1, 2026, at 8:00 a.m. ET with Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center*

NEW YORK, Nov. 17, 2026 /PRNewswire/ -- **Actinium Pharmaceuticals, Inc.** (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies with the potential to transform cancer treatment, today provided a third quarter 2026 corporate update highlighting recent clinical progress with ATNM-400, initiation of its RADIANZ pan-tumor imaging study, and advancements across its broader pipeline. With ATNM-400 now in clinical development for prostate cancer and multiple clinical and scientific milestones anticipated across its portfolio in 2027, Actinium is entering an important period of pipeline advancement.

"With ATNM-400 now in the clinic, we are advancing a differentiated HER3-targeted approach to alpha radiotherapy with the potential to address significant unmet needs in prostate cancer beyond PSMA," said Sandesh Seth, Actinium's Chairman and Chief Executive Officer. "Our encouraging initial clinical findings support continued dose escalation in mCRPC, while RADIANZ represents an important next step in evaluating HER3 targeting across multiple large solid tumor indications. Looking ahead, 2027 is shaping up to be an important year for Actinium, with anticipated clinical data and development milestones across ATNM-400, Actimab-A and Iomab-ACT. Together with our newly formed Scientific Advisory Board and strengthened leadership team, we believe we are well positioned to execute on these priorities and build value across our differentiated targeted radiotherapy pipeline."

Third Quarter 2026 and Recent Highlights

ATNM-400: First-in-Class HER3-Targeted Alpha Radiotherapy

- **Target disclosed and encouraging first-in-human data presented at EANM 2026.** Actinium announced HER3, an antigen distinct from PSMA and implicated in treatment resistance, as the target of ATNM-400 and presented initial results from the ongoing HERACT-PRO-1 Phase 1/2a study in mCRPC. The first cohort cleared the 1.0 µCi/kg dose level with no dose-limiting toxicities, and imaging showed tumor uptake retained through Day 7. Dose escalation has advanced to 1.5 µCi/kg and is ongoing. The study was also featured at ESMO 2026.
- **RADIANZ pan-tumor imaging study enrolling to inform development beyond prostate cancer.** The first patient was dosed in RADIANZ, a HER3 PET imaging study in advanced lung, breast, colorectal, pancreatic and ovarian cancers designed to inform ATNM-400 development beyond prostate cancer.

- **Preclinical data reinforce ATNM-400's pan-tumor potential.** New data presented at EANM demonstrated antitumor activity across non-small cell lung cancer (NSCLC), colorectal and ovarian cancer models, supporting the potential of ATNM-400 as a monotherapy and in combination with established treatments. Additional preclinical findings highlighting activity across breast cancer models will be presented at SABCS 2026.

Hematology Programs

- **Four abstracts accepted for presentation at ASH 2026:** Presentations will highlight long-term safety findings for Actimab-A plus CLAG-M in relapsed or refractory AML, as well as Iomab-ACT's potential as a targeted conditioning agent for CAR T-cell and gene therapies.

Corporate

- **Formed Scientific Advisory Board** of leading experts in prostate cancer, hematologic malignancies, radiochemistry and nuclear medicine: Karim Fizazi, MD, PhD (Centre Oscar Lambret and Paris-Saclay University); Sergio A. Giralt, MD (Memorial Sloan Kettering Cancer Center); Jason S. Lewis, PhD (Memorial Sloan Kettering Cancer Center); Michael J. Morris, MD (Memorial Sloan Kettering Cancer Center); and Neeta Pandit-Taskar, MD, MBA (University of Pittsburgh Medical Center).
- **Strengthened leadership team with key appointments.** Appointed Matt David, M.D., as Chief Financial Officer, bringing more than 20 years of public company finance, capital markets and investment banking experience, most recently at CorMedix, and Sean Maenpaa as Senior Vice President, Business Development, a radiopharmaceutical business development veteran from Bayer, Clovis Oncology and Telix Pharmaceuticals.
- **Financial position:** Cash and cash equivalents of $28.7 million as of September 30, 2026 are expected to fund operations through 2027.

Upcoming Events

- **December 1 – KOL Webinar on ATNM-400**: Actinium will host a webinar at 8:00 a.m. ET featuring Michael J. Morris, MD, Prostate Cancer Section Head at Memorial Sloan Kettering Cancer Center. The discussion will focus on unmet needs in mCRPC, the potential for HER3-targeted alpha radiotherapy beyond PSMA, and management's review of previously reported HERACT-PRO-1 clinical findings and the RADIANZ imaging study. Register here.
- **December 8-11 – SABCS 2026:** Actinium will present preclinical data demonstrating ATNM-400's activity across therapy-resistant breast cancer models, further supporting its potential across multiple solid tumor indications. The poster presentation is scheduled for December 9, 2026.
- **December 12-15 – ASH 2026:** Actinium will present clinical findings from its Actimab-A and Iomab-ACT programs, highlighting continued development in AML, CAR T-cell conditioning and gene therapy conditioning.

Looking ahead, Actinium expects a steady cadence of clinical data, scientific presentations and development milestones throughout 2027 as it advances ATNM-400 in prostate cancer and evaluates its broader solid tumor potential, alongside continued progress across its

hematology pipeline. In addition, Actinium continues to establish in-house manufacturing capabilities to support its clinical programs and expects to be operational by around year-end.

About Actinium Pharmaceuticals, Inc.

Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The Company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its pipeline spans three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. Actinium also holds approximately 250 patents and patent applications, including intellectual property related to cyclotron-based production of Actinium-225. For more information, please visit www.actiniumpharma.com.

About ATNM-400

ATNM-400 is an investigational antibody radioconjugate that pairs the HER3-targeting monoclonal antibody barecetamab with the alpha-emitting isotope Actinium-225. Its antibody-based design combines antigen-specific targeting with the potential for sustained tumor localization, supporting prolonged delivery of high-energy alpha radiation. Tumor uptake and retention observed through Day 7 with the ^{89}Zr-labeled imaging counterpart support this development rationale alongside the approximately 10-day half-life of ^{225}Ac. The theranostic approach enables noninvasive visualization of antibody distribution to inform therapeutic development. The program is being evaluated in a first-in-human dose-escalation Phase 1/2a study of ATNM-400 in mCRPC, HERACT-PRO-1, which utlizes Zirconium-89-labeled barecetamab PET imaging to assess tumor targeting, biodistribution and dosimetry. Actinium is also conducting an imaging study, RADIANZ (Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89) using PET to guide the pan-tumor development of ATNM-400 in various solid tumors outside of prostate cancer.

ATNM-400 is differentiated from PSMA-targeted radiotherapies by its focus on HER3, an antigen implicated in tumor survival and treatment resistance. PSMA-directed approaches include Novartis' Pluvicto and a broad pipeline of investigational therapies, including Telix Pharmaceuticals' TLX591-Tx, Clarity Pharmaceuticals' ^{67}Cu-SAR-bisPSMA, Convergent Therapeutics' CONV01-α, AstraZeneca's AZD2265 (formerly FPI-2265), Curium's lutetium-177 zadavotide guraxetan (^{177}Lu-PSMA-I&T), ARTBIO's AB001 and AdvanCell's ADVC001. These programs span small-molecule and antibody-based therapies using beta- or alpha-emitting isotopes. ATNM-400 combines HER3 targeting with an Actinium-225 antibody radioconjugate, offering a distinct biological approach with the potential to expand radiotherapy across the broad mCRPC population, including patients with PSMA-low or PSMA-negative disease and those who do not respond to or progress following PSMA-directed treatment. Its HER3-directed mechanism also supports investigation beyond prostate cancer in other HER3-expressing solid tumors.

About HER3

HER3, also known as ERBB3, belongs to the epidermal growth factor receptor family and

participates in signaling pathways that promote tumor growth, survival and treatment resistance. HER3-directed antibody-drug conjugates (ADCs) in clinical development include BioNTech and MediLink's BNT326/YL202; Bristol Myers Squibb and SystImmune's EGFR × HER3 bispecific ADC, izalontamab brengitecan (iza-bren); and Daiichi Sankyo and Merck's patritumab deruxtecan (HER3-DXd). These programs highlight clinical development interest in HER3 as an oncology target. ATNM-400 takes a different payload approach, delivering alpha radiation rather than a conventional cytotoxic drug. Preclinical activity in prostate, non-small cell lung, breast, colorectal and ovarian cancer models supports investigating ATNM-400 as a potential pan-cancer radiotherapy, both as monotherapy and in rational combinations.

Forward-Looking Statements

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995 regarding future events or future financial performance of the Company, which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from anticipated or estimated future results, including risks and uncertainties associated with the conduct, timing and results of the ongoing first-in-human HERACT-PRO-1 Phase 1/2a study of ATNM-400 and the RADIANZ imaging study, including the possibility that preliminary results may differ from final results and that preclinical results may not be predictive of clinical outcomes; the sufficiency of the Company's cash resources to fund its planned operations; the potential of product candidates; clinical trials; actions by the FDA and other governmental agencies; regulatory clearances; market demand for and acceptance of the Company's products and services; performance of clinical research organizations; and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, each as amended and supplemented from time to time.

Investors Contact:
Peter (PJ) Kelleher
LifeSci Advisors
pkelleher@lifesciadvisors.com
(617) 430-7579

View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-provides-third-quarter-2026-corporate-update-highlighting-atnm-400-and-other-business-progress-302941318.html

SOURCE Actinium Pharmaceuticals, Inc.